For asthma treatment Singulair should be taken in the evening. In the treatment of allergic rhinitis dose may be taken at any time of the day by the patient.Patients suffering from bronchial asthma and allergic rhinitis should take one tablet of once a day in the evening. Adults aged 15 years and older The dose for adults and children over 15 years is one film-coated tablets of 10 mg per day. Children aged 6 to 14 years Dosage for children 6-14 years of age is one tablet chewing 5 mg per day. Selection of dosing for this age group is not required. General Recommendations The therapeutic effect of masteron dosage on parameters that reflect the course of bronchial asthma develops during the first day. The patient should continue taking in period to achieve control of asthma symptoms, as well as during periods of worsening asthma. For older patients, patients with renal insufficiency and in patients with mild or moderate hepatic impairment, and also depending on the specific gender dose titration is not required. Appointment of in conjunction with other treatments for asthma can be added to the patient’s treatment with bronchodilators and inhaled corticosteroids (See. Section “Interactions with other medicinal products”).
Side effects :
In general, masteron dosageis well tolerated. Side effects are usually mild and usually did not require discontinuation of treatment. The overall incidence of adverse events reported with the use of was comparable to that of placebo:
hypersensitivity reactions (including anaphylaxis, angioedema, rash, pruritus, urticaria and rarely eosinophilic infiltrates of the liver); uzelklvuyu erythema, unusual vivid dreams; hallucinations; drowsiness;irritability; agitation including aggressive behavior; fatigue; suicidal ideation and suicidal behavior (suicidality) insomnia; paresthesia / hypoesthesia, very rarely – seizures; nausea, vomiting, diarrhea, abdominal pain; headache; arthralgia; myalgia; muscle cramps; the trend to increased bleeding, bruising formation; palpitations; swelling.
Data on overdose symptoms while taking patients with asthma in a dose exceeding 200 mg / day for 22 weeks and at a dose of 900 mg / day for 1 week is not found.
There are reports of acute overdose Montelukast in children (reception not less than 150 mg per day). Clinical and laboratory data at the same time demonstrate compliancemasteron dosage safety profile in children’s safety profile in adults and elderly patients. The most common adverse events were thirst, somnolence, mydriasis, hyperkinesia and abdominal pain.
Treatment is symptomatic.
The possibility of elimination of montelukast Data by peritoneal dialysis or hemodialysis is not.
Interaction with other drugs :
Masteron dosage may be administered together with other drugs traditionally used for the prevention and long term treatment of bronchial asthma. The recommended clinical dose of montelukast did not have a clinically meaningful effect on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol / norethindrone 35/1), terfenadine, digoxin and warfarin.
The is reduced in patients while receiving phenobarbital (approximately 40 %), but correcting dosing regimen in such patients is not required.
Treatment with bronchodilators: can be added to the treatment of patients whose asthma is not controlled by the use of one bronchodilator. Upon reaching the therapeutic effect (usually after the first dose) against singular therapy, bronchodilators can gradually reduce the dose.
Inhaled glucocorticosteroids: Treatment provides additional therapeutic benefit to patients receiving treatment with inhaled corticosteroids. Following stabilization, the patient’s condition may reduce the dose of corticosteroids. The dose of corticosteroids should be reduced gradually under medical supervision. Some patients receiving inhaled corticosteroids can be completely canceled. We do not recommend sharp replacement therapy with inhaled glucocorticosteroids appointment .
Special instructions :
Recommended for the treatment of acute asthma attacks. In acute bronchial asthma patients should be prescribed drugs for the acute and warning asthma therapy.
The dose used in conjunction with inhaled glucocorticosteroids can reduce gradually under medical supervision. . should not be abruptly replaced inhaled or oral corticosteroids
reduce systemic doses of corticosteroids in patients receiving anti-asthma agents, including blockers of leukotriene receptors, followed in rare cases, the appearance of one or more of the following phenomena: eosinophilia, vascular rash, worsening pulmonary symptoms, cardiac complications, and / or neuropathy sometimes diagnosed as Churg-Strauss syndrome – a systemic eosinophilic vasculitis.Although a causal relationship between these adverse events from treatment leukotriene-receptor antagonist has not been established, while reducing the systemic dose corticosteroids in patients taking , be careful and conduct the appropriate clinical follow-up. Use in the elderly age-related differences in the efficacy and safety profiles of masteron dosage not revealed.